NOD 小鼠新发糖尿病中重复给予抗 CD3 抗体不改变单疗程疗效
该研究在新发糖尿病 NOD 小鼠中比较了低剂量抗 CD3 抗体单疗程(第 0–4 天,2.5 µg/天静注)与早期(第 14–18 天)或晚期(第 43–47 天)重复给药的效果。单疗程使 17/40 只(43%)小鼠糖尿病逆转,但早期和晚期重复给药均未改善无应答小鼠的结局,也未使已缓解小鼠复发;胰腺应答小鼠出现效应 T 细胞向初始表型偏移及耗竭表型 T 细胞增多。
要点
- 单疗程低剂量抗 CD3 可使 43%(17/40)新发糖尿病 NOD 小鼠逆转。
- 早期或晚期重复给药均未提高无应答小鼠的缓解率。
- 重复给药未导致已缓解小鼠复发,耐受性良好。
核心结论
- 单疗程抗 CD3 治疗可使部分新发糖尿病 NOD 小鼠逆转,但早期或晚期重复给药不增强疗效,且在已逆转小鼠中耐受良好。
研究设计与样本
- 研究为 NOD 小鼠实验研究;新发糖尿病小鼠接受第 0–4 天低剂量抗 CD3(2.5 µg/天静注)后,分为早期(第 14–18 天)或晚期(第 43–47 天)第二疗程。
主要发现
- 单疗程抗 CD3 逆转糖尿病 17/40 只(43%)。
- 早期与晚期重复给药在无应答小鼠中均未诱导缓解(分别为 0/10 和 0/5)。
- 重复给药未使已缓解小鼠复发,早期组 5/5、晚期组 23/23 维持正常血糖。
- 无论治疗反应或方案,炎症标志物均一过性升高。
- 胰腺应答小鼠 CD4⁺ 与 CD8⁺ T 细胞由效应表型(CD62L⁻CD44⁺)向初始表型(CD62L⁺CD44⁻)明显偏移,且 PD1⁺KLRG1⁺ 耗竭表型 T 细胞频率升高;无应答小鼠胰腺 NK(NKp46⁺CD3⁻)细胞比例升高。
临床怎么用
- 结果提示抗 CD3 抗体重复给药未必增益,临床决策需权衡再治疗的必要性。
局限性
- 研究为 NOD 小鼠模型,结果外推至人类 2 型或 3 期 1 型糖尿病需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS/HYPOTHESIS: Uncertainty exists regarding the effectiveness of redosing teplizumab, a humanised anti-CD3 monoclonal antibody, in individuals with stage 2 and 3 type 1 diabetes. This study aimed to investigate the impact of redosing an anti-CD3 antibody on disease reversal and immune responses in NOD mice. METHODS: New-onset diabetic NOD mice were treated with a short course (days 0-4) of low-dose anti-CD3 (2.5 µg/day i.v.), followed by a second treatment course administered either early (days 14-18) or late (days 43-47) following the initial course. Diabetes outcomes, anti-drug antibody titres, inflammatory markers and the profiles of peripheral blood and pancreatic immune cells were assessed. RESULTS: A single course of anti-CD3 therapy reversed type 1 diabetes in 17 out of 40 treated mice (43%). However, neither early nor late redosing improved therapeutic outcomes in non-responder mice or disrupted re-established tolerance in responder mice. Early redosing, administered at the time of CD3⁺ T cell repopulation, and late redosing, timed when anti-drug antibody titres declined after their peak at 14 days, failed to induce remission in non-responder mice (0/10 and 0/5, respectively). Importantly, redosing did not trigger relapse in mice that had achieved remission following the initial treatment course, with all remaining normoglycaemic (5/5 with early redosing; 23/23 with late redosing). Inflammatory markers increased transiently, regardless of treatment response or regimen. In the pancreas, responder mice had a pronounced shift from an effector (CD62L⁻CD44⁺) to a naive (CD62L⁺CD44⁻) phenotype in both CD4⁺ and CD8⁺ T cells, independent of treatment regimen, indicative of a more regulated immune environment. These mice also exhibited elevated frequencies of CD4⁺ and CD8⁺ T cells with an exhausted (programmed cell death protein 1 [PD1]⁺killer cell lectin-like receptor subfamily G, member 1 [KLRG1]⁺) profile in their pancreas, a trait not observed in non-responder mice. Furthermore, the proportion of natural killer (NK) (NKp46⁺CD3⁻) cells was enriched in the pancreas of non-responder mice. CONCLUSIONS/INTERPRETATION: These findings suggest that while a single course of anti-CD3 therapy can be effective in a subset of mice, redosing does not enhance efficacy yet is well tolerated in previously reversed mice.
引用
- Wouters A, Lemaitre P, Degroote L, et al. Redosing of anti-CD3 antibodies in NOD mice with new-onset diabetes does not alter the effect of a single treatment course. Diabetologia. 2025. PMID: 41261242. doi:10.1007/s00125-025-06604-2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。